Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study

BMC Nephrology

Table 3 Physical performance data divided in three groups according to the assigned intervention

Variables	Exercise group	Dopamine agonists group	Placebo group
STS- 5 (sec)
Baseline	10.12±2.56	8.89±0.74	9.69±0.46
6-m post	8.24±2.34†	8.48±1.72	8.81±0.66
Δ Change	−1.75±2.32	- 0.41±1.63	- 0.88±0.76
95% CI of Δ change	−3.03 to −0.47	−1.91 to 1.09	−1.58 to −0.18
STS-30 (rep)
Baseline	14.73±4.00	14.83±2.13	14.75±0.9
6-m post	17.84± 4.68†	14.50±2.58	17.25±3.2
Δ Change	2.96±4.87	- 0.33±2.33	2.50±2.51
95% CI of Δ change	5.65 to 0.27	−0.63 to −0.03	4.81 to −0.19
STS-60 (rep)
Baseline	27.95±8.38	26.60±3.64	30.0±3.16
6-m post	32.50±9.34	27.40±7.40	32.0±5.35
Δ Change	4.26±8.23	0.80±4.65	2.00±3.26
95% CI of Δ change	8.77 to −0.25	5.09 to −3.49	5.0 to −1.0
Normal Walk (sec)
Baseline	6.09±1.24	5.69±1.53	5.30±1.06
6-m post	5.81±1.49	6.14±1.63	5.38±1.09
Δ Change	−0.42±1.36	0.44±1.46	0.07±0.27
95% CI of Δ change	−1.17 to 0.33	1.78 to −0.90	0.31 to −0.17
Fast Walk (sec)
Baseline	3.86±0.66	3.57±0.40	3.77±0.47
6-m post	3.65±0.75	3.56±0.40	3.57±0.41
Δ Change	−0.28±0.65	- 0.01±0.19	- 0.19±0.40
95% CI of Δ change	−0.63 to 0.07	−0.18 to 0.16	−0.55 to 0.17
NSRI test (sec)
Baseline	84.46±21.35	70.10±20.46	52.48±14.24
6-m post	75.02±26.60†	67.68±20.78	53.44±17.13
Δ Change	−9.25±13.41	−2.41±6.52	0.96±4.01
95% CI of Δ change	−16.6 to −1.85	−8.41 to 3.59	4.65 to −2.73

All data are mean ± SD. Abbreviations: STS-5 Sit-to- stand test 5-repetitions, STS-60 Sit-to- stand test 60 seconds, STS-30 Repetitions’ measurement at 30 seconds as part of the STS-60 test, NSRI North staffordshire royal infirmary test.
†Significantly different from the respective baseline value.